Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Japan Tissue Engineering Co's quarterly market cap
increased
from Sep. 2025 (円20,386 Mil) to Dec. 2025 (円25,259 Mil) but then
declined
from Dec. 2025 (円25,259 Mil) to Mar. 2026 (円24,204 Mil).
Japan Tissue Engineering Co's annual market cap
declined
from Mar. 2024 (円27,168 Mil) to Mar. 2025 (円18,559 Mil) but then
increased
from Mar. 2025 (円18,559 Mil) to Mar. 2026 (円24,204 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Japan Tissue Engineering Co's Enterprise Value for Today is 円31,577 Mil.
Japan Tissue Engineering Co (TSE:7774) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Japan Tissue Engineering Co Market Cap Related Terms
Japan Tissue Engineering Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7774 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Japan Tissue Engineering Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Japan Tissue Engineering Co Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Japan Tissue Engineering Co's Market Cap falls into.
Japan Tissue Engineering Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Tissue Engineering Co (TSE:7774) has a Market Cap of 円34,925 Mil as of Aug. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Japan Tissue Engineering Co and its competitors. According to the industry distribution chart, Japan Tissue Engineering Co ranks #600 out of 1422 companies in the Biotechnology industry, placing it in the top 42.2%.
Is Japan Tissue Engineering Co's Market Cap too high?
Japan Tissue Engineering Co's current Market Cap is 円34,925 Mil. Based on the distribution chart, Japan Tissue Engineering Co ranks #600 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Japan Tissue Engineering Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Japan Tissue Engineering Co ranks #600 out of 1422 companies for Market Cap. This puts Japan Tissue Engineering Co in the upper half of its industry. The industry median Market Cap is 122.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.31, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Japan Tissue Engineering Co and its competitors. For the Biotechnology industry, the median Market Cap is 122.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Japan Tissue Engineering Co's current Market Cap is 円34,925 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Significantly Overvalued. The stock's GF Value™ is 円505.19, compared to a current price of 円860.00 — trading 70.2% above its estimated fair value. The current Market Cap is 円34,925 Mil. Japan Tissue Engineering Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Market Cap is 円34,925 Mil as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円860.00 is trading 70.2% above its estimated GF Value™ of 円505.19.
GuruFocus considers Japan Tissue Engineering Co to be Significantly Overvalued.
Key valuation signals for TSE:7774:
Market Cap: 円34,925 Mil
GF Value™: 円505.19 vs. price of 円860.00 (70.2% above fair value)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
58GF Score
Get the complete analysis for TSE:7774
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
